PerkinElmer Inc
LSE:0KHE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
82.59
126.9044
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 0KHE stock under the Base Case scenario is 1.8 USD. Compared to the current market price of 97.84 USD, PerkinElmer Inc is Overvalued by 98%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for PerkinElmer Inc.
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
|
| US |
|
Waters Corp
NYSE:WAT
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
PerkinElmer’s diagnostic segment saw extraordinary pandemic-driven revenue, and a sustained decline in COVID-19 testing presents a risk that the company won’t be able to fully replace that high-margin business with other offerings, threatening overall profit growth.
Recent acquisitions, including those in the applied genomics and proteomics fields, could lead to integration challenges. Failure to harmonize product lines and maintain service quality could dilute PerkinElmer’s brand reputation and create expensive inefficiencies in its supply chain.
Heavier competition from well-capitalized peers, such as Danaher and Thermo Fisher Scientific, may intensify pricing pressure and slow the company’s expansion in life science instrumentation, particularly in emerging markets where PerkinElmer is attempting to capture new share.
PerkinElmer’s strong foothold in highly specialized analytical and detection instruments differentiates it in niche markets, driving repeat business and enabling premium pricing, particularly in the pharmaceutical and biotech sectors.
Ongoing investment in research and development, especially in advanced technologies such as next-generation sequencing and high-throughput screening, supports long-term product innovation and improves PerkinElmer’s competitive edge for future market opportunities.
The firm’s growth in food and environmental testing solutions continues to open new revenue channels, leveraging global demand for more sophisticated testing protocols and aligning with regulatory trends favoring stricter safety standards.
Revenue & Expenses Breakdown
PerkinElmer Inc
Balance Sheet Decomposition
PerkinElmer Inc
| Current Assets | 2.1B |
| Cash & Short-Term Investments | 931.4m |
| Receivables | 680.3m |
| Other Current Assets | 532.1m |
| Non-Current Assets | 10B |
| PP&E | 668.2m |
| Intangibles | 9B |
| Other Non-Current Assets | 300.4m |
| Current Liabilities | 1.2B |
| Accounts Payable | 175.8m |
| Accrued Liabilities | 463.1m |
| Other Current Liabilities | 583.8m |
| Non-Current Liabilities | 3.5B |
| Long-Term Debt | 2.6B |
| Other Non-Current Liabilities | 909.6m |
Free Cash Flow Analysis
PerkinElmer Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
PerkinElmer Inc
|
Revenue
|
2.8B
USD
|
|
Cost of Revenue
|
-1.3B
USD
|
|
Gross Profit
|
1.6B
USD
|
|
Operating Expenses
|
-1.2B
USD
|
|
Operating Income
|
366.5m
USD
|
|
Other Expenses
|
-129m
USD
|
|
Net Income
|
237.5m
USD
|
0KHE Profitability Score
Profitability Due Diligence
PerkinElmer Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
PerkinElmer Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
0KHE Solvency Score
Solvency Due Diligence
PerkinElmer Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
PerkinElmer Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0KHE Price Targets Summary
PerkinElmer Inc
According to Wall Street analysts, the average 1-year price target for 0KHE is 115.51 USD with a low forecast of 86.34 USD and a high forecast of 142.56 USD.
Dividends
Current shareholder yield for 0KHE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one 0KHE stock under the Base Case scenario is 1.8 USD.
Compared to the current market price of 97.84 USD, PerkinElmer Inc is Overvalued by 98%.